ProCE Banner Activity

Phase Ib/II Study of Neoadjuvant Chemotherapy + Pembrolizumab for Muscle-Invasive Urothelial Cancer

Capsule Summary
Conference Coverage

Results from this phase Ib/II trial suggest neoadjuvant therapy with chemotherapy plus pembrolizumab is effective and well-tolerated for patients with muscle-invasive urothelial cancer.

Released: February 22, 2023

Expiration: February 21, 2024

No longer available for credit.


Provided by

ProCE Banner


This activity is supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.